wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q28066272-EBCC70FF-7CE9-4641-9252-1DE73F24B66A
Q28066272-EBCC70FF-7CE9-4641-9252-1DE73F24B66A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q28066272-EBCC70FF-7CE9-4641-9252-1DE73F24B66A
ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
P2860
Q28066272-EBCC70FF-7CE9-4641-9252-1DE73F24B66A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q28066272-EBCC70FF-7CE9-4641-9252-1DE73F24B66A
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
eb93467e59000e047287e6f4a8e279d026c1556f
P2860
PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic color